---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122322"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:17:56.871741+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Acadia Q3 total revenue $250.4M (+18% YoY); net income $32.8M vs year-ago loss

## Summary
- NUPLAZID sales $159.2M (+10% YoY); DAYBUE sales $91.2M (+36% YoY).
- Net income $0.20 per share vs ($0.40) loss; nine-month net income $82.7M.
- Full-year guidance: NUPLAZID $600-610M, DAYBUE $340-350M, total revenue $940-960M.
- Entered agreement to sell Rare Pediatric Disease PRV for $150M; one-third of net to Neuren.
- Health Canada approved DAYBUE for Rett syndrome under Priority Review.

## SEC filing metadata
- accession: 0000950170-24-122322
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000095017024122322/0000950170-24-122322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000095017024122322/acad-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122322
- JSON: https://secwatch.observer/filing/0000950170-24-122322.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122322.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.